Free Shipping at All Times!!!!  No Minimum!!!

News

March 2, 2018


USEF Ruling Medroxyprogesterone Acetate / Depo-Provera

THE ADMINISTRATION OF MEDROXYPROGESTERONE ACETATE (DEPO-PROVERA®)
EFFECTIVE 9/1/17

The USEF requires a Medroxyprogesterone acetate disclosure form (MPA) be filed for horses treated with MPA if the horse has received treatment within three months of the competition start date. This usage data, along with additional proprietary research, will be assessed once available and further recommendations, if indicated, will be made at that time. An online version of the MPA disclosure form is available and a penalty may be incurred for not filing the report.

There are differing opinions on the use of MPA and its effects. This recommendation is a methodical and careful step in the process, allowing time for the USEF to collect and analyze data for a better understanding of how MPA is being used and its effects on competition horses, as well as assisting in the determination of withdrawal times.